Open-Label Extension to Evaluate the Long-Term Safety, Tolerability and Analgesic Efficacy

Phase 3 Completed 239 enrolled Endo USA Inc., a Keenova Therapeutics Company

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the long-term safety and tolerability of oxymorphone ER as an analgesic in cancer and lower back pain subjects having chronic moderate to severe pain.

Timeline

Start: 2001-03
Primary completion: 2003-07
Completion: 2003-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Oxymorphone	Small molecule	—	—

Indications

No indication recorded.